The recently launched Goldman Prize complements the Rowley Prize as a clinical equivalent by recognising lifetime contributions to the management of patients with CML. From the nominations for the Goldman Prize the iCMLf Directors selected Dr Rüdiger Hehlmann as the recipient for 2014. The decision was made due to the incredibly important contributions he made that have improved the outcomes for CML patients globally.
On Sept 26, at the start of the International CML Conference, the iCMLf awarded the 2013 Rowley Prize to Dr Connie Eaves, a distinguished scientist at Terry Fox Laboratories (Canada). The Rowley Prize is awarded annually by the iCMLf to an individual who has made a major lifetime contribution to the understanding of the biology of CML and/or the management of patients with CML.
In 2012 the Rowley Prize for persons who have made major contributions to the
biology and/or clinical management of CML was awarded to George Q Daley, who is the Samuel E. Lux IV Professor of Haematology/Oncology at the Children’s Hospital in Boston. Dr Daley received his PhD from MIT in 1989 and his MD summa cum laude from Harvard Medical School in 1991.
Professor John M. Goldman has a long-standing interest in the biology and therapy of CML. He was until 2004 Chairman of the Department of Haematology at Imperial College London, Director of the Leukaemia Research Fund Centre for Adult Leukaemia and Clinical Director of the Haematology Department at the Hammersmith Hospitals NHS Trust. Thereafter he took up a 2-year appointment as Fogarty Scholar at the National Institutes of Health in Bethesda USA. He is now active as Emeritus Professor of Haematology at Imperial College London and Medical Director of the Anthony Nolan Trust.
The winner of the Rowley Prize for 2010 is MD Moshe Talpaz, awarded at the start of the ESH-iCMLf meeting in September 2010 in Washington DC. Dr Janet Rowley has kindly given the iCMLf permission to name this award in her honour. Dr Moshe Talpaz is Associate Chief of the Division of Hematology/Oncology at the University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, USA. He is one of the leading clinical investigators in hematologic malignancies worldwide.
Dr Brian Druker is Joint Professor, Cell and Developmental Biology and JELD-WEN Chair of Leukemia Research at the Oregon Health and Science University. He is also an HHMI scholar. Dr Druker was responsible for bringing imatinib, the first tyrosine kinase inhibitor, to the clinic for patients with CML.